On September 7, 2024, Miskawaan Health Group (hereinafter referred to as “Miskawaan Health Group”) signed an exclusive cooperation agreement with the senior management of Sichuan Jiuzhang Biological Science and Technology Co., Ltd. (herein after referred to as “Jiuzhang Biotech”), authorizing Miskawaan Health Group to import, distribute and use the patented chlorogenic acid products of Jiuzhang Biotech in Thailand.

To effectively address the global aging trend and advance research and innovation in longevity medicine, the Global Symposium on Longevity Medicine was held at Shenzhen Lansheng Brain Hospital on August 24.

On September 25, 2021, the highly anticipated 6th China Pharmaceutical Innovation and Investment Conference was successfully held in Suzhou. At this venture capital conference, Jiuzhang Biotech reported on-site the discovery process of the target of chlorogenic acid and the progress of the Phase I/II clinical trials for the treatment of recurrent glioblastoma.

On October 17, 2019, the final symposium of the Major New Drug Creation Project "Phase I/II Clinical Research of CHA for Injection, a First-Created Class 1 New Drug" was held at the Institute of Materia Medica, Chinese Academy of Medical Sciences. The symposium was presided over by Zhang Jie, General Manager of Sichuan Jiuzhang Biotechnology Co., Ltd. Jiang Jiandong, Director of the Institute of Materia Medica, delivered a welcome speech, and Hu Jinfeng, Director of the Scientific Research Department, introduced the participants.

The "4th China Pharmaceutical Innovation and Investment Conference" grandly opened on September 21, 2019, at the Jinji Lake International Conference Center in Suzhou, Jiangsu Province, China. Guests from the four well - known global stock exchanges (Hong Kong, NASDAQ, London, and Shanghai Stock Exchanges) and top immunotherapy scientists gathered on the scene. They heatedly discussed the financing policies of globally leading financing platforms for pharmaceutical innovation enterprises, helped domestic biomedical enterprises find suitable cross - border financing channels, and promoted the improvement of the innovation and transformation capabilities of China's pharmaceutical industry.

The clinical trial titled "A Randomized, Controlled, Open-Label, Multi-center, Phase II/III Clinical Study to Evaluate the Safety and Efficacy of CHA for Injection in the Treatment of Recurrent Grade IV Glioblastoma (GBM)" was officially launched at Chongqing University Cancer Hospital on April 25, 2019, and at Cancer Hospital of Harbin Medical University on May 7, 2019. It publicly recruited recurrent glioblastoma patients who met the inclusion criteria from the society.